Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P080011/S195

Biofmity XR Torie (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear

CooperVision, Inc. · Decision date Feb 2, 2026

FDA DECISIONP080011/S195

What did the FDA decide?

FDA records P080011/S195 as a supplement to PMA P080011, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 2, 2026.

FDA approval order statement

introduction of Biofinity XR Toric (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear on Biofinity Medium Volume Line 13 at the CooperVision, Inc. facility located in Hamble, UK
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Feb 2, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P080011/S195
Regulatory pathway
PMA supplement
Product code
LPM
Decision code
OK30
Decision date
Feb 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lenses, soft contact, extended wear.

Product code
LPM
FDA device class
3

For the original device and its historical approval scope, see PMA P080011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P080011 · Original PMA

    BIOFINITY (COMFILCON A)

  2. P080011/S180 · Related supplement

    up&up Monthly Performance, up&up Monthly Performance XR, up&up Monthly Performance for Astigmatism, up&up Monthly Perfor

  3. P080011/S184 · Related supplement

    up&up Monthly Performance +

  4. P080011/S186 · Related supplement

    iWear oxygen presbyopia

  5. P080011/S192 · Related supplement

    Biofinity Toric Multifocal and Biofinity XR Toric (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear

  6. P080011/S191 · Related supplement

    Sofmed breathables XW NEXT

  7. P080011/S193 · Related supplement

    Biofinity XR Toric and Biofinity Toric Multifocal (Comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear

  8. P080011/S194 · Related supplement

    comfilcon A Soft (Hydrophilic) Contact Lenses for daily wear

  9. P080011/S195 received

    Application receipt date recorded by FDA.

  10. P080011/S195 · FDA decision

    30-Day Notice

  11. P080011/S196 · Related supplement

    Biofinity Sphere and Biofinity Toric (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear

  12. P080011/S197 · Related supplement

    Biofinity Toric (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear

  13. P080011/S198 · Related supplement

    Biofinity Toric Multifocal (comfilcon A) Soft (Hydrophilic) Contact Lenses for Extended Wear

  14. P080011/S199 · Related supplement

    Biofinity Sphere, Biofinity XR Sphere, Biofinity Energys, Biofinity Toric, Biofinity XR Toric, Biofinity Multifocal; Bio

  15. P080011/S200 · Related supplement

    Biofinity Sphere, Biofinity XR Sphere, Biofinity Energys, Biofinity Toric, Biofinity XR Toric, Biofinity Multifocal; Bio

  16. P080011/S201 · Related supplement

    Biofinity Sphere; Biofinity XR Sphere; Biofinity Energys; Biofinity Toric; Biofinity XR Toric; Biofinity Multifocal

  17. P080011/S202 · Related supplement

    comflicon A Soft (Hydrophilic) Contact Lenses for Extended Wear

  18. P080011/S203 · Related supplement

    comfilcon A Soft (Hydrophilic) Contact Lenses for Extended Wear

  19. P080011/S204 · Related supplement

    BIOFINITY (COMFILCON A)

Timeline entries are records held by MedtechLedger for P080011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P080011

Product / regulatory recordCompanyPathwayDecision dateSource
CooperVision, Inc.PMA approvalNov 19, 2008FDA
CooperVision, Inc.PMA supplementJul 23, 2025FDA
CooperVision, Inc.PMA supplementAug 20, 2025FDA
CooperVision, Inc.PMA supplementAug 20, 2025FDA
CooperVision, Inc.PMA supplementSep 22, 2025FDA
CooperVision, Inc.PMA supplementDec 5, 2025FDA
CooperVision, Inc.PMA supplementDec 11, 2025FDA
CooperVision, Inc.PMA supplementJan 7, 2026FDA
CooperVision, Inc.PMA supplementFeb 10, 2026FDA
CooperVision, Inc.PMA supplementMar 4, 2026FDA
CooperVision, Inc.PMA supplementMar 4, 2026FDA
CooperVision, Inc.PMA supplementMar 18, 2026FDA
CooperVision, Inc.PMA supplementApr 9, 2026FDA
CooperVision, Inc.PMA supplementMay 4, 2026FDA
CooperVision, Inc.PMA supplementJun 16, 2026FDA
CooperVision, Inc.PMA supplementJul 7, 2026FDA
CooperVision, Inc.PMA supplementSep 2, 2026FDA

Explore the linked device profile

Other records with product code LPM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

CooperVision, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6101 Bollinger Canyon Rd., Suite 500, San Ramon, CA, 94583

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records